rian.ie - Results

A A A

Current Search:	'Cancer' in all fields;

Displaying Results 151 - 175 of 2482 on page 7 of 100

Mark

All Ireland cancer statistics 1994-96 a joint report on incidence and mortality on the island of Ireland (2001)

National Cancer Registry Ireland; Northern Ireland Cancer Registry

Mark

An oral cancer screening study of high risk individuals (2008)

O'Sullivan, Eleanor

Mark

Androgen receptor signaling in prostate cancer development and progression (2011)

LONERGAN, PETER EOIN

Mark

Transferrin conjugation does not increase the efficiency of liposomal Foscan during in vitro photodynamic therapy of oesophageal cancer (2013)

EHRHARDT, CARSTEN; SENGE, MATHIAS; PASZKO, EDYTA

Mark

Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. (2002)

PIDGEON, GRAHAM

Mark

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. (2009)

HUGHES, DAVID JOHN

Mark

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines (2011)

RANI, SWETA; O'DRISCOLL, LORRAINE

Mark

The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer (2011)

O'BYRNE, KEN; BARR, MARTIN; GRAY, STEVEN

Mark

The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer (2011)

GRAY, STEVEN; BARR, MARTIN; O'BYRNE, KEN

Mark

Correlation of p16(INK4A) expression and HPV copy number with cellular FTIR spectroscopic signatures of cervical cancer cells. (2011)

MARTIN, CARA; O'LEARY, JOHN

Mark

Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. (2014)

O'NEILL, LUKE; LYSAGHT, JOANNE; CONROY, MELISSA

Mark

Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival (2013)

MURRAY, JAMES

Mark

Using resource modelling to inform decision making and service planning: The case of colorectal cancer screening in Ireland (2013)

WALSH, CATHAL; WALTON, CLAIR

Mark

Improving outcomes for people with skin tumours including melanoma (update) (2010)

Northern Ireland Cancer Network (NICaN)

Mark

University Research Proposal Submission Topics 2010 (2010)

Northern Ireland Cancer Network (NICaN)

Mark

Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention. (2014)

O'LEARY, JOHN; GALLAGHER, MICHAEL

Mark

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. (2015)

Johnstone, Cameron N; Smith, Yvonne E; Cao, Yuan; Burrows, Allan D; Cross, Ryan SN; Lin...

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. (2015)

Johnstone, Cameron N; Smith, Yvonne E; Cao, Yuan; Burrows, Allan D; Cross, Ryan SN; Ling, Xiawei; Redvers, Richard P; Doherty, Judy P; Eckhardt, Bedrich L; Natoli, Anthony L; Restall, Christina M; Lucas, Erin; Pearson, Helen B; Deb, Siddhartha; Britt, Kara L; Rizzitelli, Alexandra; Li, Jason; Harmey, Judith H; Pouliot, Normand; Anderson, Robin L

Abstract:

The original article is available at <a href="http://www.biologists.com">www.biologists.com</a>
The translation of basic research into improved therapies for breast cancer patients requires relevant preclinical models that incorporate spontaneous metastasis. We have completed a functional and molecular characterisation of a new isogenic C57BL/6 mouse model of breast cancer metastasis, comparing and contrasting it with the established BALB/c 4T1 model. Metastatic EO771.LMB tumours were derived from poorly metastatic parental EO771 mammary tumours. Functional differences were evaluated using both in vitro assays and spontaneous metastasis assays in mice. Results were compared to non-metastatic 67NR and metastatic 4T1.2 tumours of the 4T1 model. Protein and transcript levels of markers of human breast cancer molecular subtypes were measured in the four tumour lines, as well as p53 (Tp53) tumour-suppressor gene status and responses t...

https://epubs.rcsi.ie/mctart/74

Mark

Lipid Raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration. (2012)

Donatello, Simona; Babina, Irina S; Hazelwood, Lee D; Hill, Arnold DK; Nabi, Ivan R; Ho...

Mark

An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models. (2011)

Donatello, Simona; Hudson, Lance; Cottell, David C; Blanco, Alfonso; Aurrekoetxea, Igor...

Mark

Development and validation of a clinical prediction rule to identify suspected breast cancer: a prospective cohort study (2014)

Galvin, Rose; Joyce, Doireann; Downey, Eithne; Boland, Fiona; Fahey, Tom; Hill, Arnold K

Mark

South Central Strategic Health Authority: Cancer inequalities (2007)

Oxford Cancer Intelligence Unit

Mark

Reply: cost-effectiveness of population-based screening for colorectal cancer. (2013)

Sharp, Linda; Walsh, Cathal Dominic; Whyte, Sophie; Tilson, Lesley; O'Ceilleachair...

Mark

Exercise in cancer care in Ireland: a survey of oncology nurses and physiotherapists (2014)

O'Hanlon, É.; Kennedy, N.

Mark

Cancer mortality in Ireland: 1976-1986. (1987)

Seymour, Colin; Herity, Bernadette; Moriarty, Michael J.

Mark

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. (2016)

Messager, Mathieu; Mirabel, Xavier; Tresch, Emmanuelle; Paumier, Amaury; Vendrely, Véro...

Messager, Mathieu; Mirabel, Xavier; Tresch, Emmanuelle; Paumier, Amaury; Vendrely, Véronique; Dahan, Laetitia; Glehen, Olivier; Vasseur, Frederique; Lacornerie, Thomas; Piessen, Guillaume; El Hajbi, Farid; Robb, William B; Clisant, Stéphanie; Kramar, Andrew; Mariette, Christophe; Adenis, Antoine

Abstract:

The original article is available at www.biomedcentral.com
BACKGROUND: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy regimens in this setting is a combination of a fluoropyrimidin and of a platinum analogue. Due to the promising results of the recent CROSS trial, another regimen combining paclitaxel and carboplatin is also widely used by European and American centers. No clinical study has shown the superiority of one treatment over the other. The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments. Our aim is to evaluate, in operable esophageal and gastro-esophageal junctional cancer, the complete resection rate and severe postoperative morbidity rate associated with these two neoadjuvant chemo...

https://epubs.rcsi.ie/surgart/32